Nov. 7 at 5:16 PM
$SLS You absolutely Know Big Pharma Will be Adding AML CR1 Patient and AML Post Asct Patient Populations to the Potential Revenue Calculations.
- Especially Since the
$ABBV VIALE-T P-Asct Phase 3 Trial Failure, and the
$RHHBY VIALE-M CR1 Maintenance Phase 3 Trial Failures.
50,000 AML CR1/P-Asct Patients EACH YEAR
-
$260K REV per Patient in Year 1 =
$13B TAM
$13B Total Addressable Market
And then compound it with Gps Immunotherapy Infinite dosing Regime.
